Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.86 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | GAK | O14976 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 4/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 4/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | CLK1 | P49759 | 1/20 | 0.64 |
| ▸ | KIF5B | P33176 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939454 | 0.93 | EGFR (1.00) | EGFRABCG2SRCGAKLCK | |
| SCHEMBL5864703 | 0.88 | EGFR (0.84) | EGFRABCG2GAKLCKKDR | |
| SCHEMBL2100607 | 0.88 | EGFR (1.00) | EGFRABCG2SRCGAKLCK | |
| SCHEMBL12485595 | 0.82 | KDR (0.83) | EGFRABCG2SRCGAKLCK | |
| SCHEMBL6181483 | 0.81 | EGFR (1.00) | EGFRABCG2SRCGAKLCK | |
| SCHEMBL31067608 | 0.81 | KDR (0.85) | EGFRKDR | |
| Hydrochloric Acid SCHEMBL6179766 | 0.80 | EGFR (1.00) | EGFRABCG2SRCGAKLCK | |
| SCHEMBL28643875 | 0.80 | EGFR (0.82) | EGFRABCG2SRCLCKKDR | |
| SCHEMBL5864588 | 0.79 | EGFR (0.67) | EGFRABCG2SRCGAKLCK | |
| SCHEMBL5864555 | 0.79 | KDR (0.73) | EGFRSRCGAKLCKPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039002-A1 | 6,7-Dimethoxyquinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2004-02-26 | — | — | US | claimed |
| JP-2002540103-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | claimed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | claimed |
| US-6358962-B2 | ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS | PARKER HUGHES INSTITUTE | 2002-03-19 | — | — | US | claimed |
| EP-1162974-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | claimed |
| EP-1163228-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | claimed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | claimed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | claimed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| US-7038049-B2 | Haloanilino quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2005-04-07 | — | — | US | disclosed |
| US-20040039002-A1 | 6,7-Dimethoxyquinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2004-02-26 | — | — | US | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| EP-1163228-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | disclosed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885ABCG2 351/4885SRC 2416/4885 |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | EGFR 3336/4885ABCG2 19/4885SRC 3595/4885 |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885ABCG2 351/4885SRC 2416/4885 |
| US-20040039002-A1 | 6,7-Dimethoxyquinazolines and therapeutic use thereof | HRH2, HNMT, HRH4 | EGFR 1601/4885ABCG2 765/4885SRC 1852/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885ABCG2 351/4885SRC 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.